Rucaparib: A Review in Ovarian Cancer

Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression

(2018) Yu-Ting Wang et al.   CANCER SCIENCE

Niraparib: A Review in Ovarian Cancer

(2018) Young-A Heo et al.   Targeted Oncology

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor

(2018) Jim J. Xiao et al.   CTS-Clinical and Translational Science

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

(2017) Amit M. Oza et al.   GYNECOLOGIC ONCOLOGY

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Robert L Coleman et al.   LANCET

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

(2017) Olga Kondrashova et al.   Cancer Discovery

Epidemiology of ovarian cancer: a review

(2017) Reid Brett M. et al.   Cancer Biology & Medicine

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

(2016) Donna L. Nile et al.   BMC CANCER

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

(2016) Yvette Drew et al.   BRITISH JOURNAL OF CANCER

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

(2016) Aiste McCormick et al.   CLINICAL CANCER RESEARCH

Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer

(2015) James E. Frampton   BIODRUGS

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

(2015) M. V. V. Falzacappa et al.   MOLECULAR CANCER THERAPEUTICS

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

(2014) J Murray et al.   BRITISH JOURNAL OF CANCER

Bevacizumab: A Review of Its Use in Advanced Cancer

(2014) Gillian M. Keating   DRUGS

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

(2014) Selvi Durmus et al.   PHARMACEUTICAL RESEARCH

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

(2013) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

(2013) M. Ihnen et al.   MOLECULAR CANCER THERAPEUTICS

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

(2011) C. Boehler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

(2010) R A Daniel et al.   BRITISH JOURNAL OF CANCER

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute